CLn Skin Care, a leader in dermatologist-developed therapeutic skincare, is proud to announce the launch of its new Hypochlorous Acid Spray, an FDA-cleared (510k Medical Device, HOCL 125 ppm, parts per million, concentration) daily cleansing solution designed to soothe, refresh, and support the natural healing of normal, irritated, sensitive, and damaged skin.

Dr. Javad Sajan at Allure Esthetic is the best facial feminization surgeon in the U.S.

Groundbreaking Observational Study Reveals 88% of Participants Experienced Significant Health Improvements, Offering Unprecedented Hope in the Fight Against the World's Number One Killer

In partnership with RxERP Financial, the program offers up to $350,000 per pharmacy and $1 million per wholesaler or manufacturer through trusted third-party financing partners, strengthening cash flow and supply chain resilience.

Recognition in breast augmentation and liposuction highlights Dr. Doherty's expertise in two of the most requested cosmetic procedures, underscoring his reputation for natural outcomes and patient-centered care.

The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix, a next generation GnRH Antagonist as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer

D-MNA and Teverelix collectively represent ~$8 billion in potential market opportunity

Comprehensive 2025 FootRenew Review With Real User Results, Common Complaints, Triple Method Technology Details, and Current Pricing

Full year fiscal 2025 net revenue of $66.4 million

Full year fiscal 2025 net loss of $13.6 million

Full year fiscal 2025 adjusted EBITDA¹ of $9.2 million

$31.0 million cash balance at June 30, 2025

Exclusive agreement in June 2025 to commercialize EXXUA™ (gepirone) extended-release tablets ("EXXUA") is expected to serve as a major growth catalyst; the Company anticipates launching EXXUA in the fourth calendar quarter of 2025 as a centerpiece of its commercial efforts as it enters the over $22 billion United States prescription major depressive disorder ("MDD") market with what the Company believes to be a novel first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD

Company to host conference call and webcast today, September 23, 2025, at 4:30 p.m. Eastern time

Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Macular Degeneration

Strategic collaboration expands CBDL's footprint in the booming East Coast cannabis market projected to surpass $33 billion by 2030, while strengthening retail distribution and cross-brand synergies

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups

Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains

- Spora takes role in international consortium aiming to turn CO₂ into protein enough to feed more than 1 billion people every year

Connectivity failures, OS updates, and frustrated patients shouldn't be your problem. Silent devices, outsourced call centers, and disengaged patients create hidden risks and liability. Addison Care delivers fully integrated Virtual Care - engaging patients, protecting providers, and maximizing Medicare value.

Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The drug showed rapid and predictable absorption, a favorable duration of action supporting once-daily dosing, and no CNS side effects typically seen with ketamine.

Full 2025 Hewelth Pulse Oximeter Review with Pros, Cons, Pricing, and Key Complaints for Smarter Buying Decisions

Comprehensive 2025 Guide to RxTra Clinical Trials: In-Depth Reviews, Top Complaints, Pricing Facts, Key Features, and Proof of Legitimacy

IBYC, based in Richmond, BC, is a next-generation digital health company developing AI-powered telemedicine and wearable solutions to improve access to care anytime, anywhere. The company focuses on mobile health monitoring, senior and multilingual populations, and caregiver support through secure, real-time biometric data analysis and AI insights. Founded by entrepreneurs with 20+ years of China-Canada experience, IBYC integrates technology, compliance, and cross-border resources to build scalable, culturally competent healthcare platforms.

Addressing care gaps as 700,000 BC residents lack family doctors and seniors are set to grow 68% over the next two decades

Kevin R. Hanz, MD: Dallas' Choice for Best in Cosmetic Surgery, Liposuction, and Breast Augmentation

New in vitro results show Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, potentially representing a novel frontier in epigenetic therapy where no existing candidates have shown comparable breadth.

The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV risk Prostate Cancer collecting representing ~ $6 billion in potential market opportunity

Missing the signs of spondyloarthritis delays diagnosis and treatment.

New Capabilities Place Peer-reviewed Literature Review Evidence at the Fingertips of Research and Commercial Teams to Align Decision-making and Improve Productivity

Leadership change positions NCQA for the next generation of quality improvement.

Keensight Capital ("Keensight"), one of the leading private equity managers dedicated to pan-European Growth Buyout ^[1] investments, today announced it has agreed to acquire a majority stake in Isto Biologics ("Isto") from Thompson Street Capital Partners ("TSCP"). TSCP will retain a minority stake, alongside Isto Biologics' management team.

Industry-recognized expert SciBite, and Pistoia Alliance Board Member, joins Rancho to advance structured data solutions for life sciences innovation

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies

Icotrokinra also showed sustained skin clearance and favorable safety profile in both adults and adolescents at Week 52 in Phase 3 ICONIC-LEAD study

Preclinical proof-of-concept data on PN-881, a first-in-class oral peptide targeting the IL-17 pathway, and part of Protagonist's fully owned development pipeline, including the highly potent and selective binding of IL-17A and IL-17F

- Abstract highlights additional primary and secondary data from Phase 3 STAR-1 clinical study of XYNGARI™ for the treatment of moderate-to-severe acne -

PowerBite Reviews 2025: Full Ingredient List, Side Effects, Pricing, Complaints, and Legit Check

Ahead of MEDITECH LIVE 2025 this week, Black Book releases survey findings from 128 hospital clients, conducted prior to the event.

Black Book survey: IT modernization is the lever to keep home health nurses and protect access as Medicare rate changes loom

Mass General Brigham expands the reach of its Medicare-approved Benson-Henry Institute Intensive Cardiac Rehabilitation program through virtual and center-based partnerships

11 Health Plans Earn Top 5-Star Rating

Sustained acoustic medicine helps athletes bridge that critical gap between recovery and performance by providing an advanced, non-invasive therapy proven to accelerate healing and reduce pain